Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266692 · ClinicalTrials.gov registry record · Phase 1
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cogent Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03266692 is a Phase 1 study that was terminated before completion, run by Cogent Biosciences. The registered enrollment target is 15 participants.
The verdict
NCT03266692, a Phase 1 study, was terminated before completion, sponsored by Cogent Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.
Interventions
- BIOLOGICAL ACTR087
- BIOLOGICAL SEA-BCMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266692
The ClinicalTrials.gov registry entry for NCT03266692 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ACTR087 is the first listed.
NCT03266692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03266692 about?
NCT03266692 is a clinical study titled "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma". This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.
What is the current status of trial NCT03266692?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-02-22. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03266692?
The interventions under investigation include: ACTR087 (BIOLOGICAL), SEA-BCMA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03266692?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.